Economic Factors as Major Determinants of Ustekinumab Drug Survival of Patients with Chronic Plaque Psoriasis in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of biologic agents for psoriasis, particularly in Asian countries. Objective: To determine the drug survival for ustekinumab in real-life settings and investigate the factors affecting drug survival for psoriasis patients in Korea. Methods: We evaluated 98 psoriasis patients who were treated with ustekinumab at a single center. We analyzed the efficacy and drug survival of ustekinumab. Cox proportional hazard analysis and competing risk regression analysis were performed to reveal the factors affecting the drug survival of ustekinumab. Results: The overall mean drug survival was 1,596 days (95% confidence interval [CI], 904∼2,288). Among the 39 cessations of ustekinumab treatment, 9 (23.1%) patients discontinued treatment after experiencing satisfactory results. Multivariate Cox proportional hazard analysis revealed that paying on patients’ own expense was the major predictor for the discontinuation of ustekinumab (hazard ratio [HR], 9.696; 95% CI, 4.088∼22.998). Competing risk regression analysis modeling of discontinuation because of factors other than satisfaction of an event also revealed that ustekinumab treatment at the patient’s expense (HR, 4.138; 95% CI, 1.684∼ 10.168) was a predictor of discontinuation rather than satisfaction. Conclusion: The results of our study revealed that the cost of biologics treatment affects the drug survival of ustekinumab and suggested that economic factors affect the drug survival of ustekinumab treatment in Korea.
Abstract
Background: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of biologic agents for psoriasis, particularly in Asian countries. Objective: To determine the drug survival for ustekinumab in real-life settings and investigate the factors affecting drug survival for psoriasis patients in Korea. Methods: We evaluated 98 psoriasis patients who were treated with ustekinumab at a single center. We analyzed the efficacy and drug survival of ustekinumab. Cox proportional hazard analysis and competing risk regression analysis were performed to reveal the factors affecting the drug survival of ustekinumab. Results: The overall mean drug survival was 1,596 days (95% confidence interval [CI], 904∼2,288). Among the 39 cessations of ustekinumab treatment, 9 (23.1%) patients discontinued treatment after experiencing satisfactory results. Multivariate Cox proportional hazard analysis revealed that paying on patients’ own expense was the major predictor for the discontinuation of ustekinumab (hazard ratio [HR], 9.696; 95% CI, 4.088∼22.998). Competing risk regression analysis modeling of discontinuation because of factors other than satisfaction of an event also revealed that ustekinumab treatment at the patient’s expense (HR, 4.138; 95% CI, 1.684∼ 10.168) was a predictor of discontinuation rather than satisfaction. Conclusion: The results of our study revealed that the cost of biologics treatment affects the drug survival of ustekinumab and suggested that economic factors affect the drug survival of ustekinumab treatment in Korea.
참고문헌 (19)
- 최종원, "The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice", Annals of Dermatology, 29(1), pp.55~60 (2017), 대한피부과학회
- Ramirez-Fort MK, "Continuous versus intermittent therapy for moderate-to-severe psoriasis", Clin Exp Rheumatol, 31, pp.S63~S70 (2013)
- Kimball AB, "Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis:results from the PHOENIX 1 trial through up to 3 years", Br J Dermatol, 166, pp.861~872 (2012)
- Vilarrasa E, "ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice", J Am Acad Dermatol, 74, pp.1066~1072 (2016)
- Shalom G, "Biologic drug survival in Israeli psoriasis patients", J Am Acad Dermatol, 76, pp.662~669.e1 (2017)
- Zweegers J, "Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry", Br J Dermatol, 175, pp.340~347 (2016)
- van den Reek JM, "'Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network", Br J Dermatol, 171, pp.1189~1196 (2014)
- Gniadecki R, "Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris", Br J Dermatol, 172, pp.244~252 (2015)
- van den Reek JM, "Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis", Br J Dermatol, 170, pp.415~424 (2014)
- Nickoloff BJ, "What have we learned in dermatology from the biologic therapies?", J Am Acad Dermatol, 54, pp.S143~S151 (2006)
- Puig L, "Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis", Dermatology, 230, pp.46~54 (2015)
- Menter A, "Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis", J Am Acad Dermatol, 73, pp.410~419.e6 (2015)
- Kimball AB, "Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study", J Eur Acad Dermatol Venereol, 27, pp.1535~1545 (2013)
- Vergou T, "Five-year experience with ustekinumab for psoriasis: real-life data of a single centre", J Eur Acad Dermatol Venereol, 31, pp.e40~e41 (2017)
- Marinas JE, "Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: a Canadian multicentre retrospective study", Australas J Dermatol, 59, pp.e11~e14 (2018)
- Warren RB, "Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)", J Invest Dermatol, 135, pp.2632~2640 (2015)
- Arnold T, "Drug survival rates and reasons for drug discontinuation in psoriasis", J Dtsch Dermatol Ges, 14, pp.1089~1099 (2016)
- Jacobi A, "Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis", Int J Dermatol, 55, pp.296~302 (2016)
- Staidle JP, "A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency", Expert Opin Pharmacother, 12, pp.2041~2054 (2011)